In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Acura Pharmaceuticals, Inc. (NASDAQ:ACUR). The analyst placed a $1.00 price target on the stock which indicates a 23.46% upside to the last closing price. In the year following Vernon’s ratings, the stocks covered yield an average return of -13.2% according to TipRanks.com. In the past year 12 out of 56 recommendations or 21% were successful.
Wall Street sell-side analysts have placed a $1 one year price target on Acura Pharmaceuticals, Inc. (NASDAQ:ACUR). This is the consensus average based on 1 firms who have recently issued reports on the equity.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell,Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is ranked 1 based on 1 broker recommendations. Of the 1 analyst estimates, the most bullish sees the stock reaching $1 within the next 12 months while the most bearish analyst sees the stock at $1 within the year.
Taking a look at the long term growth prospects of the stock, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
According to analysts, Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is expected to report earnings per share for the current fiscal quarter of $N/A. This is the consensus mean estimate based on the individual covering sell-side firm’s reported numbers. The company last reported earnings for the period ending on 2014-12-31 of $-0.06.
Acura Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Impede Technology is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. As of December 31. 2012, the Company had seven additional opioid products utilizing Aversion in various stages of development.